Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

700
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
700
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

749
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
749
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

876
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
876
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

691
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
691
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

28
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
28

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endoscopic closure of a malignant entero-vaginal fistula using a cardiac septal occluder device.

Endoscopy international open·2026
Same author

Distinct systemic metabolic signatures in premenopausal women with lipedema revealed by composite indices.

Frontiers in endocrinology·2026
Same author

The Gastrointestinal Barrier-Mechanisms of Barrier Dysfunction in Liver Cirrhosis and Spontaneous Bacterial Peritonitis.

Biomedicines·2026
Same author

Severe organophosphate intoxication without classic cholinergic signs: A case report and updated literature review.

Science progress·2026
Same author

Acute liver failure linked to Mycobacterium genavense in newly diagnosed HIV infection.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Mechanisms and trade-offs of fat-powered endurance flight in migratory animals.

The Journal of experimental biology·2026
Same journal

Vunakizumab for IL-17A-Mediated Diseases: A Review in Psoriasis and Spondyloarthritis.

Biologics : targets & therapy·2026
Same journal

Immunological Biomarkers in Glioblastoma: Targeting T and NK Cells for Enhanced Diagnosis and Prognosis.

Biologics : targets & therapy·2026
Same journal

MicroRNA-661 Suppresses Proliferation and Migration of Pulmonary Artery Smooth Muscle Cells and Endothelial Cells by Targeting CCND2.

Biologics : targets & therapy·2026
Same journal

Vunakizumab and Acitretin for Elderly Refractory Generalized Pustular Psoriasis: A Case Report and Comprehensive Literature Review.

Biologics : targets & therapy·2026
Same journal

Rapid Resolution of Psoriasis Following Low-Dose Interleukin-2 Monotherapy: A Case Report.

Biologics : targets & therapy·2026
Same journal

Long-Term TIE2 Inhibition in a TEK-Mutated Venous Malformation: A 3-Year Clinical Experience.

Biologics : targets & therapy·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.0K

Golimumab in unresponsive ulcerative colitis.

Elisabeth Lippert1, Martina Müller1, Claudia Ott1

  • 1University Hospital Regensburg, Department of Internal Medicine I, Regensburg, Germany.

Biologics : Targets & Therapy
|June 7, 2014
PubMed
Summary
This summary is machine-generated.

Ulcerative colitis (UC) treatment has evolved from symptom management to achieving remission and healing. Newer therapies like golimumab offer new options for mild to moderate UC when other treatments fail.

Keywords:
anti-TNFbiological therapyinflammatory bowel disease

More Related Videos

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

2.5K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.9K

Related Experiment Videos

Last Updated: Apr 28, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.0K
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

2.5K
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

1.9K

Area of Science:

  • Gastroenterology
  • Immunology

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease primarily affecting the colon.
  • Traditional treatments focused on symptom relief using mesalazine and steroids.
  • Evolving therapeutic goals now emphasize long-term remission and mucosal healing.

Purpose of the Study:

  • To review the advancements in ulcerative colitis (UC) treatment.
  • To highlight the role of newer therapies, including biologics.
  • To introduce golimumab as a novel treatment option for mild to moderate UC.

Main Methods:

  • Review of current literature on UC treatment strategies.
  • Analysis of the efficacy and application of established and emerging therapies.
  • Focus on the therapeutic landscape including immunomodulators and anti-tumor necrosis factor (TNF) agents.

Main Results:

  • Mesalazine is effective for mild UC.
  • Moderate to severe UC often requires azathioprine or anti-TNF therapy, with variable success rates.
  • A significant portion of patients do not respond or lose response to existing treatments, necessitating further options.

Conclusions:

  • The treatment paradigm for UC has shifted towards achieving deeper remission and mucosal healing.
  • Anti-tumor necrosis factor (TNF) therapies and immunomodulators are crucial for moderate to severe UC.
  • Golimumab represents a promising new therapeutic avenue for patients with mild to moderate UC, addressing unmet needs.